Joel Beatty
Stock Analyst at Baird
(4.55)
# 263
Out of 5,048 analysts
200
Total ratings
50.31%
Success rate
31.61%
Average return
Main Sectors:
Stocks Rated by Joel Beatty
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMLX Amylyx Pharmaceuticals | Maintains: Outperform | $10 → $19 | $13.93 | +36.40% | 5 | Oct 16, 2025 | |
| LRMR Larimar Therapeutics | Maintains: Outperform | $10 → $7 | $3.89 | +79.95% | 3 | Sep 30, 2025 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $50 → $67 | $34.98 | +91.54% | 3 | Sep 9, 2025 | |
| EDIT Editas Medicine | Maintains: Outperform | $4 → $6 | $3.08 | +94.81% | 5 | Aug 13, 2025 | |
| COGT Cogent Biosciences | Maintains: Neutral | $7 → $9 | $16.30 | -44.79% | 6 | Jul 8, 2025 | |
| ELF e.l.f. Beauty | Maintains: Outperform | $110 → $145 | $122.14 | +18.72% | 8 | Jun 6, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $28 → $31 | $22.70 | +36.56% | 4 | May 19, 2025 | |
| NGNE Neurogene | Downgrades: Neutral | $38 → $24 | $34.26 | -29.95% | 5 | May 16, 2025 | |
| ARGX argenx SE | Upgrades: Outperform | $680 | $818.50 | -16.92% | 7 | May 13, 2025 | |
| DNLI Denali Therapeutics | Maintains: Outperform | $30 → $29 | $16.28 | +78.13% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $66 | $68.31 | -3.38% | 15 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $167 → $155 | $137.54 | +12.69% | 4 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $160 → $162 | $134.99 | +20.01% | 5 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $41 | $30.70 | +33.55% | 3 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $16 | $14.20 | +12.68% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $16 | $11.01 | +45.32% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $117 → $73 | $198.76 | -63.27% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $32 | $21.27 | +50.45% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $75 | $54.22 | +38.33% | 1 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $7 | $1.89 | +270.37% | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $72 → $65 | $53.57 | +21.34% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $72 | $34.60 | +108.09% | 4 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $540 → $240 | $1.54 | +15,484.42% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $4.5 | $1.26 | +257.14% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $12.94 | +93.20% | 3 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $9 | $0.45 | +1,912.52% | 2 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $28 | $13.70 | +104.38% | 2 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $1.83 | +774.32% | 1 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $1.25 | $2.06 | -39.32% | 2 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $44 | $1.68 | +2,519.05% | 3 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $58 | $42.39 | +36.82% | 6 | Feb 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $24 | $31.86 | -24.67% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $18 | $9.97 | +80.54% | 3 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $6 | $2.35 | +155.32% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $36 → $28 | $5.96 | +369.80% | 2 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $170 → $175 | $456.04 | -61.63% | 2 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 | $4.35 | +221.84% | 8 | Jan 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $108 | $24.01 | +349.81% | 10 | Jan 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $78 | $74.30 | +4.98% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $14.64 | +583.06% | 2 | Apr 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $480 → $120 | $16.22 | +639.83% | 14 | Apr 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $480 → $450 | $4.04 | +11,038.61% | 2 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $2.97 | - | 12 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $15 | $8.40 | +78.57% | 11 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $120 | $0.55 | +21,718.18% | 2 | Aug 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $19 | $10.27 | +85.00% | 3 | Nov 10, 2017 |
Amylyx Pharmaceuticals
Oct 16, 2025
Maintains: Outperform
Price Target: $10 → $19
Current: $13.93
Upside: +36.40%
Larimar Therapeutics
Sep 30, 2025
Maintains: Outperform
Price Target: $10 → $7
Current: $3.89
Upside: +79.95%
Dianthus Therapeutics
Sep 9, 2025
Maintains: Outperform
Price Target: $50 → $67
Current: $34.98
Upside: +91.54%
Editas Medicine
Aug 13, 2025
Maintains: Outperform
Price Target: $4 → $6
Current: $3.08
Upside: +94.81%
Cogent Biosciences
Jul 8, 2025
Maintains: Neutral
Price Target: $7 → $9
Current: $16.30
Upside: -44.79%
e.l.f. Beauty
Jun 6, 2025
Maintains: Outperform
Price Target: $110 → $145
Current: $122.14
Upside: +18.72%
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Outperform
Price Target: $28 → $31
Current: $22.70
Upside: +36.56%
Neurogene
May 16, 2025
Downgrades: Neutral
Price Target: $38 → $24
Current: $34.26
Upside: -29.95%
argenx SE
May 13, 2025
Upgrades: Outperform
Price Target: $680
Current: $818.50
Upside: -16.92%
Denali Therapeutics
May 8, 2025
Maintains: Outperform
Price Target: $30 → $29
Current: $16.28
Upside: +78.13%
May 7, 2025
Maintains: Outperform
Price Target: $70 → $66
Current: $68.31
Upside: -3.38%
May 7, 2025
Maintains: Outperform
Price Target: $167 → $155
Current: $137.54
Upside: +12.69%
May 6, 2025
Maintains: Outperform
Price Target: $160 → $162
Current: $134.99
Upside: +20.01%
May 2, 2025
Maintains: Outperform
Price Target: $38 → $41
Current: $30.70
Upside: +33.55%
Mar 7, 2025
Maintains: Outperform
Price Target: $27 → $16
Current: $14.20
Upside: +12.68%
Mar 7, 2025
Maintains: Outperform
Price Target: $32 → $16
Current: $11.01
Upside: +45.32%
Mar 3, 2025
Maintains: Outperform
Price Target: $117 → $73
Current: $198.76
Upside: -63.27%
Mar 3, 2025
Maintains: Outperform
Price Target: $28 → $32
Current: $21.27
Upside: +50.45%
Nov 25, 2024
Initiates: Outperform
Price Target: $75
Current: $54.22
Upside: +38.33%
Nov 15, 2024
Maintains: Outperform
Price Target: $6 → $7
Current: $1.89
Upside: +270.37%
Oct 30, 2024
Maintains: Neutral
Price Target: $72 → $65
Current: $53.57
Upside: +21.34%
May 31, 2024
Maintains: Outperform
Price Target: $68 → $72
Current: $34.60
Upside: +108.09%
May 15, 2024
Maintains: Outperform
Price Target: $540 → $240
Current: $1.54
Upside: +15,484.42%
Apr 30, 2024
Downgrades: Neutral
Price Target: $4.5
Current: $1.26
Upside: +257.14%
Apr 11, 2024
Maintains: Outperform
Price Target: $24 → $25
Current: $12.94
Upside: +93.20%
Mar 19, 2024
Maintains: Outperform
Price Target: $11 → $9
Current: $0.45
Upside: +1,912.52%
Oct 3, 2023
Maintains: Outperform
Price Target: $32 → $28
Current: $13.70
Upside: +104.38%
Jun 1, 2023
Initiates: Outperform
Price Target: $16
Current: $1.83
Upside: +774.32%
May 2, 2023
Maintains: Outperform
Price Target: $4 → $1.25
Current: $2.06
Upside: -39.32%
Apr 13, 2023
Initiates: Outperform
Price Target: $44
Current: $1.68
Upside: +2,519.05%
Feb 7, 2023
Maintains: Outperform
Price Target: $60 → $58
Current: $42.39
Upside: +36.82%
Nov 18, 2022
Maintains: Outperform
Price Target: $18 → $24
Current: $31.86
Upside: -24.67%
Nov 10, 2022
Downgrades: Underperform
Price Target: $18
Current: $9.97
Upside: +80.54%
Aug 29, 2022
Maintains: Outperform
Price Target: $9 → $6
Current: $2.35
Upside: +155.32%
Mar 3, 2022
Upgrades: Neutral
Price Target: $36 → $28
Current: $5.96
Upside: +369.80%
Feb 12, 2021
Downgrades: Neutral
Price Target: $170 → $175
Current: $456.04
Upside: -61.63%
Jan 14, 2021
Downgrades: Neutral
Price Target: $14
Current: $4.35
Upside: +221.84%
Jan 12, 2021
Downgrades: Neutral
Price Target: $108
Current: $24.01
Upside: +349.81%
Aug 10, 2020
Maintains: Buy
Price Target: $80 → $78
Current: $74.30
Upside: +4.98%
Apr 6, 2020
Maintains: Buy
Price Target: $140 → $100
Current: $14.64
Upside: +583.06%
Apr 1, 2020
Maintains: Buy
Price Target: $480 → $120
Current: $16.22
Upside: +639.83%
Mar 26, 2020
Maintains: Buy
Price Target: $480 → $450
Current: $4.04
Upside: +11,038.61%
Mar 17, 2020
Upgrades: Buy
Price Target: n/a
Current: $2.97
Upside: -
Sep 24, 2019
Maintains: Buy
Price Target: $19 → $15
Current: $8.40
Upside: +78.57%
Aug 17, 2018
Maintains: Neutral
Price Target: $240 → $120
Current: $0.55
Upside: +21,718.18%
Nov 10, 2017
Maintains: Buy
Price Target: $15 → $19
Current: $10.27
Upside: +85.00%